Abstract
Background: Central post-stroke pain (CPSP) is a severe and distressing pain condition. Treatment of CPSP is based on amitriptyline and anti-epileptic drugs (AED) but limited by side effects and unsatisfying efficacy. Levetiracetam (LEV) is a novel AED with a favourable adverse event and safety profile. Experimental neuropathic animal and human pain models show an analgesic effect of LEV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
